Related Experiment Videos
Locally recurrent soft tissue sarcoma of the extremities
G P Midis1, R E Pollock, N P Chen
1Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA.
Surgery
|June 17, 1998
Summary
Aggressive limb-sparing surgery and multimodal therapy offer durable local control for isolated soft tissue sarcoma (STS) recurrences in the extremity. Most patients achieve long-term survival, demonstrating the efficacy of these advanced treatment strategies.
Area of Science:
- Oncology
- Surgical Oncology
- Sarcoma Research
Background:
- Management of locally recurrent extremity soft tissue sarcoma (STS) presents significant challenges.
- Evaluating long-term outcomes for isolated local recurrence of extremity STS is crucial for treatment optimization.
Purpose of the Study:
- To assess the long-term outcomes of patients treated for isolated locally recurrent soft tissue sarcoma of the extremity.
- To identify clinicopathologic and treatment factors influencing outcomes in extremity STS recurrence.
Main Methods:
- Retrospective analysis of 36 patients with isolated locally recurrent extremity STS treated between 1980 and 1990.
- Evaluation of treatment modalities including surgery alone, combined modality therapy (surgery plus radiation and/or chemotherapy), and radiotherapy alone.
- Assessment of outcomes using local recurrence-free, recurrence-free, and overall survival rates.
Main Results:
- Limb-sparing conservative surgery was feasible in 75% of patients.
- Forty-four percent of patients experienced no further recurrence at a median follow-up of 58 months.
- Five-year actuarial survival rates were 72% for local recurrence-free, 45% for recurrence-free, and 77% for overall survival.
Conclusions:
- Limb-sparing surgery is achievable in most patients with isolated recurrent extremity STS.
- Individualized treatment strategies, including aggressive multimodality approaches, can achieve durable local control.
- These findings support the use of multimodality limb-sparing treatments for recurrent extremity STS.